低氧诱导因子和白血病细胞分化

三氧化二砷（As2O3,ATO）是一种新发现的有效治疗急性早幼粒细胞白血病（acute promyelocytic leukemia,APL）的药物。研究发现,该药物在体外诱导细胞分化的能力不如体内明显。以此为基础,最近我们意外地发现模拟低氧化合物和中度低氧环境能够直接在体外诱导急性髓系白血病细胞分化,也选择性地加强三氧化二砷诱导的APL细胞分化。进一步地,间歇性低氧能够显著延长移植的白血病小鼠生存时间,并且抑制白血病细胞浸润并诱导其分化。以这些工作为基础,我们就低氧诱导白血病细胞分化的分子机制进行了深入研究。本文将就相关工作作一综述,并讨论有待进一步研究的问题。     

铁剥夺在TPA 诱导K562 细胞分化中对细胞 生长分化及EGR1mRNA 表达的影

目的：通过,IPA诱导K562细胞分化过程中干预细胞铁代谢探讨白血病细胞铁与细胞分化的关系及对EGR1mRNA表达的影响。方法：应用体外细胞培养技术通过细胞形态,细胞化学染色观察细胞生长分化情况;用FCM、RT—PCR等技术检细胞周期、细胞表面分化抗原CD33、CD14及EGR1mRNA的表达。结果：在,IPA诱导K562细胞分化过程中铁剥夺可明显抑制K562细胞生长,并可阻止,IPA诱导K562细胞分化,使K562细胞停止在S期。铁剥夺可降低,TPA诱导K562细胞分化过程中EGR1mRNA的表达。讨论：铁剥夺明显抑制K562细胞生长、阻止TPA诱导K562细胞分化,故铁剥夺剂（DFO）可能作为一种辅助抗癌药用于白血病的化疗,但由于它能阻止白血病细胞的分化,故不宜用于白血病的诱导分化治疗。铁剥夺使K562细胞分化过程中E—GR1mRNA表达降低可能参与了阻止TPA诱导K562细胞的分化过程。     

环六亚甲基双乙酰胺体外诱导胚胎性癌B7—2细胞分化对MS_3基因表达的影响

MS_3 cDNA是多潜能胚胎性癌细胞专一的顺序,HMBA可诱导B 7—2细胞分化为原始内胚层样细胞。用定量细胞质RNA点印迹杂交法分析了MS_3基因在小鼠胚胎性癌B 7—2细胞经HMBA诱导前和诱导后的表达水平。小鼠成纤维细胞NIH3T3被用作阴性对照,MS_3基因的表达水平在B 7—2细胞经HMBA诱导5天后下降了86％。鉴于HMBA对B 7—2细胞的诱导效率约为90％,这一实验结果表明在HMBA诱导分化中,MS_3基因的表达被抑制。     

糖复合物与肿瘤细胞的诱导分化

糖复合物与肿瘤细胞的诱导分化吴兴中陈惠黎（上海医科大学生化教研组,上海２０００３２）关键词肿瘤细胞糖链变化肿瘤细胞的分化与许多因素有关。分化后的肿瘤细胞,基因型和表型均有显著改变。糖链结构作为细胞识别的分子机制和某些细胞分化标志的结构基础,在肿瘤分化...     

Wnt3a诱导小鼠胚胎干细胞向心肌细胞分化的研究

目的：研究Wnt3a在诱导小鼠胚胎干细胞心肌细胞分化中的作用和原理。方法：设计不同浓度,不同成分的Wnt3a条件培养基对小鼠胚胎干细胞诱导分化,对分化细胞进行形态学鉴定,通过免疫细胞化学检测心肌肌钙蛋白-T（cTnT）的表达,通过RT．PCR检测肌球蛋白重链（ot．MHC）和肌球蛋白轻链（MLC．2v）的表达。结果：Wnt3a诱导小鼠胚胎干细胞分化为心肌样细胞,分化细胞具有自动收缩性,免疫细胞化学检测心肌肌钙蛋白．T（cTllT）表达阳性,RT．PCR检测肌球蛋白重链（d—MHC）和肌球蛋白轻链（MLC-2v）表达阳性。经典Wnt信号途径的抑制剂Frizzled一8／Fc,能够抑制Wnt3a的诱导分化作用。结论：Wnt3a通过经典Wnt信号途径诱导小鼠胚胎干细胞向心肌细胞分化。     

核仁磷酸蛋白基因突变对K562白血病细胞分化的影响

核仁磷酸蛋白基因（nucleophosmin,NPM1）突变在急性髓系白血病的发生发展中发挥着重要作用,而与白血病分化阻滞的关系尚未完全阐明。为探讨NPM1基因突变对白血病细胞体外分化的影响,将携带NPM1 A型突变（NPM1-mA）的表达质粒载体pEGFPC1-NPM1-mA转染白血病K562细胞系,构建稳定表达NPM1-mA蛋白的细胞株（K562 mA）,同时设立野生型NPM1转染组（K562 wt）、空载体转染组（K562 C1）和未处理组（K562）为对照。利用豆蔻酰佛波醇乙酯（PMA）诱导各组细胞分化,瑞氏–吉姆萨染色观察细胞分化的形态改变,计算诱导分化率;相差显微镜计数贴壁细胞数量;流式细胞术分析细胞表面分化抗原CD41的表达。结果显示,PMA作用72 h后,与对照组相比,K562 mA组细胞的诱导分化率及贴壁细胞数明显降低（P〈0.05）;同时,CD41的表达受到显著抑制（P〈0.01）。提示NPM1基因突变能够阻滞白血病细胞系K562的体外分化。     

环六亚甲基双乙酰胺对小鼠畸胎癌B7-2克隆细胞的诱导分化

近年来,有不少研究工作者报道了用化学物质诱导恶性癌细胞进行有限的分化。这类物质主要有维生素A酸(RA),丁酸钠(Na-butyrare),二甲基亚砜(DM-SO),环腺嘌呤核苷酸(c-AMP)以及环六亚甲基双乙酰胺(hexamethylene bisaceta-mide,HMBA)等,它们能使癌细胞恶性表型受到抑制,并向一定类型的体细胞分化。HMBA最早用于研究小鼠红白血病细胞的诱导分化,并为研究珠蛋白基因表达提供了很好的实验模型。随后,Jakob等     

肿瘤治疗的新途径--中药有效成分诱导恶性肿瘤细胞分化

中药有效成分诱导肿瘤细胞分化是肿瘤细胞诱导分化治疗发展的一个新的领域。区别于直接杀灭肿瘤细胞的疗法,对机体正常细胞的负影响较小,并在毒副作用等问题上优于传统中药。其药理机制是从抑制癌基因等多种途径作用。文中主要就中药有效成分对肿瘤细胞诱导分化作用的前景进行了初步探讨。     

癌细胞的诱导分化

专一性诱导物质的发现给研究细胞分化提供了一个有利的工具。诱导正常细胞分化的诱导物能否引起癌细胞正常分化?近年来,以色列 Sachs 教授为首的实验室对不同来源的髓性白血病作了广泛的研究。发现未成熟的正常髓细胞分化为巨噬细胞和粒细胞需要巨噬细胞——粒细胞诱导物(MGI)。而髓性白血病细胞亚株     

5－氮－2＇－脱氧胞苷（5－aza－CdR）对HL－60细胞分化和DNA甲基化酶的影响

以５－氮－２＇－脱氧胞苷（５－ａｚａ－ＣｄＲ）为诱导物,在０．５μｍｏｌ／Ｌ的最佳浓度下,可诱导ＨＬ－６０细胞分化达１５％左右。同时,用［￣３Ｈ］－ｍｅｔｈｙｌ－ｓ－ａｄｅｎｏｓｙｌｍｅｔｈｉｏｎｉｎｅ（￣３Ｈ－ＳＡＭ）为底物,通过同位素参入法,测定了不同浓度诱导物对ＨＬ－６０细胞ＤＮＡ甲基化酶活力的影响,发现在最佳诱导物浓度下,可使ＨＬ－６０细胞ＤＮＡ甲基化酶活力明显下降,此外,也比较了不同分化水平的ＨＬ－６０细胞中具有不同甲基化水平的ＤＮＡ在体外接受甲基的能力,从而证明５－ａｚａ－ＣｄＲ诱导ＨＬ－６０细胞分化与其ＤＮＡ甲基化状态密切相关。     

Hydrophobic chromatography of the HL-60 cellular fraction co-binding with hexamethylene bisacetamide

Methods of separating N-acetyl-1,6-diaminohexane (NADAH) and its immobilization to diol-silica have been developed. Hexamethylene bisacetamide (HMBA) and its metabolite NADAH are used as inducers of leukemia cell differentiation. The inducing mechanism of HMBA is still not clear. Experiments show that HMBA and NADAH undergo relatively strong hydrophobic reactions and do not readily undergo ion-exchange with the proteins of the cytosolic fraction of HL-60 cells during immobilization of NADAH; the retention time of the proteins was longer than that of the phosphatides. These results show that the adsorption of HMBA and NADAH to proteins was higher than that to phosphatides. The expected biospecific receptor binding with HMBA has not been found.     

Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA)

We have previously demonstrated a number of metabolites of hexamethylene bisacetamide (HMBA) in the urine of patients treated with HMBA. These include N-acetyl-1,6-diaminohexane (NADAH), 6-acetamidohexanoic acid (6AcHA), 1,6-diaminohexane (DAH) and 6-aminohexanoic acid (6AmHA). Because these compounds have potential roles in the dose-limiting metabolic acidosis and neurotoxicity associated with HMBA therapy, and are similar in structure to known substrates of monoamine oxidase (MAO) and diamine oxidase (DAO), we investigated the activities of these enzymes in the metabolic interconversion of HMBA metabolites. NADAH (5 mM) was incubated with MAO and aldehyde dehydrogenase. 6AcHA production was verified by gas chromatography-mass spectrometry and quantified by gas chromatography. 6AcHA production was linear for up to 4 hr. Complete inhibition of MAO activity was observed with 2 mM tranyl-cypromine or pargyline. Mouse liver microsomes, which do not contain MAO, did not convert NADAH to 6AcHA and, in control experiments, did not degrade 6AcHA. The HMBA metabolite, DAH, was a substrate for DAO, producing 3,4,5,6-tetrahydro-2H-azepine. Participation of DAO in the metabolism of HMBA implies potential interaction of HMBA and metabolites with polyamine metabolism and may represent a mechanism for HMBA's effects on cellular growth and differentiation. Metabolism of NADAH, also a differentiator, by MAO implies that concurrent use of HMBA and an MAO inhibitor may be clinically useful.     

1,6-Diaminohexane contributes to the hexamethylene bisacetamide-induced erythroid differentiation pathway by stimulating Ca2+ release from inositol 1,4,5-trisphosphate-sensitive stores and promoting Ca2+ influx

Hexamethylene bisacetamide (HMBA) stimulates Ca(2+) signals in murine erythroleukemia (MEL) cells serving as an important component of the HMBA-induced pathway that promotes differentiation to the erythroid phenotype. We observed that 1,6-diaminohexane (DAH) triggered a more rapid and robust increase in MEL cell Ca(2+) levels compared to HMBA and the monodeacetylated N-acetyl-1,6-diaminohexane (NADAH), and that polyamine deacetylase inhibition completely abolished the ability of HMBA and NADAH to induce Ca(2+) signals in MEL cells. Our work indicates that DAH mediates Ca(2+) signal propagation via its ability to activate inositol 1,4,5-trisphosphate (IP(3)) receptors, as we observed similar Ca(2+) release characteristics and heparin sensitivity of DAH and IP(3) in permeabilized MEL cells. Finally, we observed that the DAH-induced Ca(2+) release pathway robustly coupled to a Ca(2+) influx pathway that could be distinguished from thapsigargin-induced Ca(2+) influx by its unusual insensitivity to 2-aminoethoxydiphenyl borate.     

Characteristics of ether-linked glycerophospholipids in Friend erythroleukaemia cells differentiated by dimethyl sulphoxide or hexamethylenebisacetamide and in non-inducible clones treated with the inducers.

The present study deals with changes in ether-linked glycerophospholids which accompany differentiation of Friend erythroleukaemia (FEL) cells by dimethyl sulphoxide (DMSO) and hexamethylenebisacetamide (HMBA). We also tested clones of FEL cells non-inducible by DMSO or HMBA for ether-linked lipid changes not related to the differentiation process. FEL cells contained appreciable proportions of alkenylacyl and alkylacyl subfractions in phosphatidylethanolamine (PE) and phosphatidylcholine (PC). Compared with FEL cells, clones non-inducible by DMSO or HMBA had a greater amount of alkenylacyl PE associated with a lack of alkenylacyl PC. The differentiation of FEL cells by DMSO or HMBA was accompanied by a reduction of alkylacyl PE and PC. DMSO- and HMBA-differentiated FEL cells showed changes in alkenyl- and alkyl-chain profiles, some of which were also observed in non-inducible FEL cells treated with DMSO or HMBA.     

Effect of aphidicolin on Friend erythroleukemia cell maturation

Aphidicolin, a specific and reversible inhibitor of DNA polymerase alpha, was examined as a potential tool to evaluate the relationship between proliferative and differentiative events in Friend erythroleukemia cell (FELC) maturation. Since FELC can be induced to differentiate along the erythrocytic pathway with a variety of inducing agents, the effects of aphidicolin were tested on proliferating FELC and cells which were induced to differentiate with the potent inducer, hexamethylene bisacetamide (HMBA). Exposure of FELC to aphidicolin resulted in unbalanced growth within 24 h, as reflected by abnormally large cells, compared with untreated cells. In the presence of 10 or 50 microM aphidicolin, 75-90% of cells became differentiated (benzidine+ cells) within 48 h, although by 72 h cells treated with aphidicolin were non-viable as determined by trypan blue staining. A wider range of aphidicolin concentrations was tested in an effort to determine the optimal concentration of aphidicolin that maximally induced differentiation with minimal loss of cell viability. Continuous exposure of FELC from 24-96 h with doses of aphidicolin ranging from 0.5 to 50 microM was more effective for differentiation induction than was short-term exposure (1, 2, 4, 12 h) to the drug, although 1 h of exposure significantly (p less than 0.01) increased differentiation (28.1 +/- 7.8%) compared with untreated cells (2.7 +/- 1.0%). When cells were treated with HMBA (5 mM) and aphidicolin (1, 5, 10 microM), in combination, aphidicolin shifted the time of onset of differentiation from 72 to 48 h, but did not act synergistically or additively with HMBA; nor was the induction effect of aphidicolin changed by HMBA. In contrast, suboptimal doses of aphidicolin (0.5 microM) in combination with HMBA (2.5 mM) produced an additive effect on FELC differentiation. In addition, [3H]thymidine experiments demonstrated that aphidicolin reversibly blocked FELC in S phase and at G1-S interface of the cell cycle. These results indicate that aphidicolin can induce the differentiation of FELC, and that a complete round of replicative DNA synthesis is not required for differentiation to occur.     

Activated macrophages distinguish undifferentiated-tumorigenic from differentiated-nontumorigenic murine erythroleukemia cells

The interaction between macrophages and differentiating cells was examined using murine erythroleukemia cells (MELC). Inflammatory macrophages activated with recombinant murine interferon-gamma (rMuIFN-gamma) and lipopolysaccharide (LPS) first specifically recognized and bound tumorigenic-undifferentiated MELC and then produced their lysis. MELC that were induced to differentiate by a 5-day treatment with 5 mM N,N'-hexamethylene-bis-acetamide (HMBA) accumulated hemoglobin (benzidine positive) and were not recognized by the macrophages. Qualitative examination by light and electron microscopy confirmed the specific nature of the macrophage-MELC interaction. Quantitative assessment showed that the binding was dependent on the temperature and divalent cations and independent of serum components. A 24-h treatment of MELC with HMBA resulted in decreased binding, prior to hemoglobin accumulation and commitment to differentiation. The lack of binding of nontumorigenic-differentiated cells by macrophages was not due to residual HMBA. It thus appears that macrophages can distinguish MELC at different stages of differentiation.     

Effect of alpha-difluoromethylornithine on DNA methylation in murine erythroleukaemic cells. Relationship to stimulation of induced differentiation.

Murine erythroleukaemic (MEL) cells cultured with alpha-difluoromethylornithine (DFMO) accumulated decarboxylated S-adenosylmethionine(decarboxylated AdoMet). In the absence of the inducer hexamethylenebisacetamide (HMBA), this accumulation of decarboxylated AdoMet was associated with a concomitant and proportional increase in DNA hypomethylation. In the presence of HMBA, DFMO, which stimulates the erythrodifferentiation of MEL cells, enhanced the differentiation-associated DNA hypomethylation. However, this differentiation-associated DNA hypomethylation was neither temporally nor quantitatively correlated with the accumulation of decarboxylated AdoMet in these cells. Therefore DFMO probably stimulates the HMBA-induced differentiation of MEL cells and the associated DNA hypomethylation via the effect of this drug on polyamine biosynthesis.     

L'hexaméthylène bisacétamide (hmba) supprime la perte de sensibilité des cellules thyroïdiennes monocouches de porc à la thyrotropine: Hexamethylenebisacetamide (HMBA) prevents the loss of TSH sensitivity in porcine thyroid monolayer cells

The polar coumpound hexamethylenebisacetamide (HMBA) is a differentiating agent in the murine erythroleukemia cell system (MELC). It induces, like dimethylsulfoxide, the commitment to terminal differentiation leading to a recovery in the expression of several genes like the globin gene. This molecule which also induces differentiation in other cellular types is a growth agent for human, ovine and porcine thyroid cells. Forty-eight hours after the onset of culture, porcine thyroid monolayer cells do not respond to thyrotropin (TSH). We demonstrate that a pretreatment from the onset of culture with HMBA of porcine thyroid cells prevents the loss of TSH-sensitivity. The TSH-sensitivity is concentration-dependent in HMBA and leads to the reorganization of cells into follicles, even in the presence of HMBA However, the withdrawal of HMBA when TSH is added is absolutely required to obtain a total recovery in iodide trapping and organification. If HMBA is present during TSH-stimulation, it inhibits iodide trapping partially but iodide organification completely. Cells remain sensitive to TSH for at least 12 days if HMBA treated, and their sensitivity is totally restored after 3, 6 or 9 days of TSH-stimulation. HMBA, which is, like TSH, a growth agent for the thyroid cell and an agent that maintains some of the specialized functions, could be a putative candidate to obtain normal human thyroid cell lines.